Human intervention for the investigation of cyclolinopeptide uptake from flaxseed
Not Applicable
Completed
- Conditions
- Healthy volunteers
- Registration Number
- DRKS00015179
- Lead Sponsor
- Technische Universität MünchenLehrstuhl für Lebensmittelchemie und molekulare Sensorik und Lebensmittelchemie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
healthy women and men, age between 20 and 40 years, written confirmed consent
Exclusion Criteria
acute illness; under- and overweight persons (BMI <18.5 or >30 kg/m2); disorders affecting absorption, digestion, metabolism, and excretion; regular medication except oral contraceptive; known allergy against flaxseed and/or an ingredient of the muffins
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method maximum concentration of cyclolinopeptides (Cmax), time til Cmax (tmax), areau under the curve (AUC), eliminationrate (kel), and elimination-half-life (t1/2) in blood and urine
- Secondary Outcome Measures
Name Time Method flaxseed biomarkers
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms facilitate cyclolinopeptide absorption from flaxseed in healthy volunteers?
How does flaxseed-derived cyclolinopeptide bioavailability compare to synthetic cyclolinopeptide formulations?
Are specific gut microbiota biomarkers associated with enhanced cyclolinopeptide uptake in DRKS00015179?
What adverse events were observed during cyclolinopeptide administration in the Technische Universität München trial?
Do lignans or other flaxseed compounds synergize with cyclolinopeptides for therapeutic applications?